Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Novo Nordisk
Novo Nordisk
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Fierce Pharma
Novo Nordisk
Rybelsus
diabetes
clinical trials
Eli Lilly
Flag link:
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
Investors Business Daily
Novo Nordisk
Ozempic
diabetes
obesity
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline
In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline
Enpoints
Dewpoint Therapeutics
Novo Nordisk
diabetes
insulin resistance
condensates
Flag link:
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Seattle Times, WA
Novo Nordisk
drug shortages
Ozempic
diabetes
weight loss
Flag link:
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Sanofi
Lantus
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
Novo Nordisk suspended from ABPI after code breach
Novo Nordisk suspended from ABPI after code breach
Pharmaphorum
Novo Nordisk
ABPI
Flag link:
Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly
Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly
BioSpace
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly
Forbes
Novo Nordisk
drug pricing
insulin
diabetes
Eli Lilly
Flag link:
Covering new weight loss drugs could strain Medicare, policy experts warn
Covering new weight loss drugs could strain Medicare, policy experts warn
Stat
obesity
Medicare
Wegovy
Novo Nordisk
Flag link:
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Fierce Pharma
Eli Lilly
Novo Nordisk
Sanofi
insulin
Bernie Sanders
drug pricing
Flag link:
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Big Pharma
Novo Nordisk
Moderna Therapeutics
Gilead Sciences
BeiGene
Flag link:
Novo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston
Novo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston
Fierce Biotech
Novo Nordisk
layoffs
hirings
R&D
Boston
Flag link:
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Fierce Pharma
Medicare
drug pricing
Merck
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
JNJ
Flag link:
Novo sows the seeds for a new heart failure approach
Novo sows the seeds for a new heart failure approach
EP Vantage
Novo Nordisk
HS-001
cell therapy
heart failure
Flag link:
Novo Nordisk apologizes for not disclosing sponsorship of anti-obesity training
Novo Nordisk apologizes for not disclosing sponsorship of anti-obesity training
Financial Times
Novo Nordisk
obesity
UK
Saxenda
Flag link:
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Pharmaphorum
Novo Nordisk
Heartseed
clinical trials
HS-001
cell therapy
heart failure
Flag link:
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'
Endpoints
Novo Nordisk
Wegovy
earnings
Flag link:
AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS
AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS
Endpoints
AstraZeneca
Sanofi
Novo Nordisk
340B
drug discounts
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »